Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2026)

Contineum Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 23.17% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 558.66% decrease from a year earlier, with the FY2025 full-year figure at -$516000.0, down 122.41% from the prior year.
• Change in Accured Expenses slipped to -$3.5 million in Q1 2026 per CTNM's latest filing, from $2.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.9 million in Q4 2024 and bottomed at -$3.5 million in Q1 2026.
• The 4-year median for Change in Accured Expenses is -$102000.0 (2025), against an average of -$11076.9.
• Across the five-year window, Change in Accured Expenses jumped 283.05% in 2024 and slumped 653.16% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.6 million in 2023, then soared by 283.05% to $2.9 million in 2024, then dropped by 28.62% to $2.1 million in 2025, then slumped by 268.1% to -$3.5 million in 2026.
• Per Business Quant, the three latest CTNM Change in Accured Expenses figures stand at -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and $351000.0 (Q3 2025).